Atripla Side Effects
Generic name: efavirenz / emtricitabine / tenofovir disoproxil
Medically reviewed by Drugs.com. Last updated on Sep 7, 2024.
Note: This document provides detailed information about Atripla Side Effects associated with efavirenz / emtricitabine / tenofovir disoproxil. Some dosage forms listed on this page may not apply specifically to the brand name Atripla.
Applies to efavirenz / emtricitabine / tenofovir disoproxil: oral tablet.
Important warnings
This medicine can cause some serious health issues
Oral route (tablet)
Severe acute exacerbations of hepatitis B virus (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), which are components of efavirenz/emtricitabine/tenofovir disoproxil fumarate.
Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue efavirenz/emtricitabine/tenofovir disoproxil fumarate.
If appropriate, initiation of anti-hepatitis B therapy may be warranted.
Precautions
It is very important that your doctor check your or your child's progress at regular visits, especially during the first few weeks that you take this medicine. Blood and urine tests may be needed to check for any unwanted effects.
Do not use this medicine together with elbasvir/grazoprevir (Zepatier®) or voriconazole (Vfend®).
The medicines in this combination tablet are also available as Complera®, Descovy®, Emtriva®, Genvoya®, Odefsey®, Stribild®, Sustiva®, Truvada®, Vemlidy®, or Viread®. Do not take the efavirenz, emtricitabine, and tenofovir combination with any of these medicines.
Using this medicine while you are pregnant can harm your unborn baby. Use 2 effective forms of birth control to keep from getting pregnant during treatment with this medicine and for 12 weeks after the last dose. Some birth control pills may not work as well while you are using this medicine. Use birth control pills together with another form of birth control, such as condoms, a diaphragm, or contraceptive foam or jelly. If you think you have become pregnant while using the medicine, tell your doctor right away.
Two rare but serious reactions to this medicine are lactic acidosis (too much acid in the blood) and liver toxicity. These are more common if you or your child are female, very overweight (obese), or have been taking anti-HIV medicines for a long time. Call your doctor right away if you have abdominal or stomach discomfort, cramping, nausea, vomiting, diarrhea, or a decreased appetite, muscle cramping or pain, unusual tiredness or weakness, trouble breathing, or yellow skin or eyes.
Contact your doctor right away if you have any changes to your heart rhythm. You might feel dizzy or faint, or you might have a fast, pounding, or uneven heartbeat. Make sure your doctor knows if you or anyone in your family has ever had a heart rhythm problem such as QT prolongation.
You might have mood or behavior changes with this medicine, such as feeling sad or hopeless, or getting upset easily. You could feel nervous or hostile, or have decreased awareness or responsiveness. Some people become violent and want to hurt themselves or others. Call your doctor right away if you or your child have any strange feelings, thoughts, or behaviors.
Some people who have used this medicine developed serious skin problems. Call your doctor right away if you or your child notice a severe skin rash, blistering, peeling, or loosening of the skin, red skin lesions, sores or ulcers on the skin, or fever or chills while you or your child are using this medicine.
This medicine may also increase your risk of developing fractures (broken bones). Ask your doctor about this if you have any concerns.
This medicine may increase the risk of kidney problems. To lower this risk, avoid other medicines that can be harmful to the kidneys such as aminoglycoside antibiotics, certain other antiviral medicines, and NSAID pain medicines.
This medicine may cause some people to become dizzy, lightheaded, drowsy, or less alert than they are normally. Even if taken at bedtime, it may cause some people to feel drowsy or less alert on arising. Be careful to limit the amount of alcohol that you drink, since alcohol can also make you drowsy. Do not drive or do anything else that could be dangerous until you know how this medicine affects you.
Your immune system may get stronger when you start taking HIV medicines. Tell your doctor right away if you or your child notice any changes in your health. Sometimes the immune system will start to fight infections that were hidden in your body, such as pneumonia, herpes, or tuberculosis. Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) may also occur.
This medicine may cause you to have excess body fat. Tell your doctor if you notice changes in your body shape, such as an increased amount of fat in the upper back and neck, or around the chest and stomach area. You might also lose fat from the legs, arms, and face.
Make sure any doctor or dentist who treats you knows that you or your child are using this medicine. This medicine may affect the results of certain medical tests.
This medicine does not decrease the risk of transmitting the HIV infection to others through sexual contact or by contaminated blood. Make sure you understand and practice safe sex, even if your partner also has HIV. Avoid sharing needles with anyone.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or non-prescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Common side effects of Atripla
Some side effects of efavirenz / emtricitabine / tenofovir disoproxil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- diarrhea
- dizziness
Less common side effects
- abnormal dreams
- decreased appetite
- decreased awareness or responsiveness
- discouragement
- feeling sad or empty
- irritability
- loss of appetite
- loss of interest or pleasure
- mild rash
- mimicry of speech or movements
- mutism
- negativism
- pain or tenderness around the eyes and cheekbones
- peculiar postures or movements, mannerisms or grimacing
- severe sleepiness
- trouble sleeping
- unusual drowsiness
Serious side effects of Atripla
Along with its needed effects, efavirenz/emtricitabine/tenofovir disoproxil may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking efavirenz / emtricitabine / tenofovir disoproxil:
Less common side effects
- blistering, peeling, or loosening of the skin
- body aches or pain
- chills
- clay-colored stools
- cough
- dark urine
- ear congestion
- fever
- headache
- itching
- loss of voice
- muscle aches
- nausea
- severe skin rash
- sore throat
- stomach pain or tenderness
- swelling of the feet or lower legs
- tightness of the chest
- trouble concentrating
- unusual tiredness or weakness
- vomiting
- yellow eyes or skin
For healthcare professionals
Applies to efavirenz / emtricitabine / tenofovir disoproxil: oral tablet.
General adverse events
The most common side effects reported with this drug were psychiatric disorders, nervous system disorders, and gastrointestinal disorders. During a clinical trial using the individual components, the most common side effects were diarrhea, nausea, headache, fatigue, dizziness, depression, insomnia, abnormal dreams, and rash.
In general, the most common side effects associated with efavirenz in combination with other antiretroviral drugs of at least moderate severity included rash, dizziness, nausea, headache, and fatigue; the most significant side effects were nervous system symptoms, psychiatric symptoms, and rash.
In general, the most common side effects associated with emtricitabine in combination with other antiretroviral drugs of mild to moderate severity included headache, diarrhea, nausea, and rash; mild and asymptomatic skin discoloration (hyperpigmentation on the palms and/or soles) occurred more often with emtricitabine than the control treatment.
In general, the most common side effects associated with tenofovir disoproxil fumarate (DF) in combination with other antiretroviral drugs were mild to moderate gastrointestinal events, including nausea, diarrhea, vomiting, and flatulence.[Ref]
Metabolic
- Very common (10% or more): Elevated fasting cholesterol (up to 22%)
- Common (1% to 10%): Anorexia, elevated fasting triglycerides, altered serum glucose, hyperglycemia, elevated alkaline phosphatase
- Uncommon (0.1% to 1%): Increased appetite
Efavirenz:
- Common (1% to 10%): Anorexia, hypertriglyceridemia
- Uncommon (0.1% to 1%): Hypercholesterolemia
- Postmarketing reports: Redistribution/accumulation of body fat (in areas such as back of neck, breasts, abdomen, retroperitoneum)
Emtricitabine:
- Common (1% to 10%): Hyperglycemia, hypertriglyceridemia
Tenofovir DF:
- Very common (10% or more): Hypophosphatemia
- Uncommon (0.1% to 1%): Hypokalemia
- Rare (less than 0.1%): Lactic acidosis
Combination antiretroviral therapy:
- Frequency not reported: Redistribution of body fat (lipodystrophy)
Antiretroviral therapy:
- Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased glucose levels[Ref]
Elevated fasting cholesterol (greater than 240 mg/dL), elevated fasting triglycerides (greater than 750 mg/dL), altered serum glucose (less than 40 mg/dL or greater than 250 mg/dL), hyperglycemia (greater than 250 mg/dL), and elevated alkaline phosphatase (greater than 550 units/L) have been reported in up to 22%, 4%, up to 3%, up to 2%, and 1% of patients, respectively.
Hypercholesterolemia and hypertriglyceridemia have also been reported during postmarketing experience with efavirenz.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.
Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Hypokalemia, lactic acidosis, and hypophosphatemia have also been reported during postmarketing experience with tenofovir.[Ref]
Gastrointestinal
- Common (1% to 10%): Diarrhea, nausea, elevated serum amylase, vomiting
- Uncommon (0.1% to 1%): Dry mouth
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Dyspepsia, abdominal pain, elevated pancreatic amylase, elevated serum lipase
Efavirenz:
- Common (1% to 10%): Dyspepsia, abdominal pain, diarrhea, vomiting, nausea
- Uncommon (0.1% to 1%): Pancreatitis
- Postmarketing reports: Constipation, malabsorption
Emtricitabine:
- Very common (10% or more): Diarrhea, nausea
- Common (1% to 10%): Elevated amylase (including elevated pancreatic amylase), elevated serum lipase, vomiting, abdominal pain, dyspepsia
Tenofovir DF:
- Very common (10% or more): Diarrhea, vomiting, nausea
- Common (1% to 10%): Abdominal pain, abdominal distension, flatulence
- Uncommon (0.1% to 1%): Pancreatitis
- Postmarketing reports: Increased amylase[Ref]
Elevated serum amylase (greater than 175 units/L) has been reported in up to 8% of patients.
Elevated pancreatic amylase (greater than 2 x ULN) and serum lipase (greater than 2 x ULN) have each been reported with emtricitabine or tenofovir in up to 3% of patients.
Pancreatitis and abdominal pain have also been reported during postmarketing experience with efavirenz and tenofovir.[Ref]
Psychiatric
- Common (1% to 10%): Depression, anxiety, insomnia
- Uncommon (0.1% to 1%): Decreased libido
Efavirenz:
- Very common (10% or more): Insomnia (up to 16.3%)
- Common (1% to 10%): Depression, anxiety, severe depression, abnormal dreams, nervousness, hallucination
- Uncommon (0.1% to 1%): Suicidal ideation, nonfatal suicide attempts, aggression, paranoia, mania, psychosis, euphoric mood, affect/emotional lability, confusional state, agitation
- Frequency not reported: Depersonalization, delirium
- Postmarketing reports: Delusions, neurosis, psychosis-like behavior, completed suicide, catatonia
Emtricitabine:
- Common (1% to 10%): Insomnia, abnormal dreams[Ref]
Serious psychiatric side effects associated with efavirenz have included severe depression, suicidal ideation, nonfatal suicide attempts, aggression, paranoia, and mania.
Aggression, agitation, affect lability, psychosis, paranoia, and mania have also been reported during postmarketing experience with efavirenz.[Ref]
Nervous system
- Common (1% to 10%): Dizziness, headache
- Uncommon (0.1% to 1%): Incoherent speech
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy)
Efavirenz:
- Very common (10% or more): Nervous system symptoms (53%), dizziness (up to 28.1%)
- Common (1% to 10%): Impaired concentration, somnolence, cerebellar coordination and balance disturbances, headache, disturbance in attention
- Uncommon (0.1% to 1%): Convulsions, amnesia, abnormal thinking, ataxia, abnormal coordination, tremor, vertigo, tinnitus
- Frequency not reported: Stupor
- Postmarketing reports: Hypoesthesia, paresthesia, neuropathy, encephalopathy
Emtricitabine:
- Very common (10% or more): Headache
- Common (1% to 10%): Dizziness
Tenofovir DF:
- Very common (10% or more): Dizziness
- Common (1% to 10%): Headache[Ref]
Nervous system symptoms of any grade and regardless of causality (53%) included dizziness, insomnia, impaired concentration, somnolence, abnormal dreams, hallucinations, amnesia, agitation, euphoria, depersonalization, confusion, abnormal thinking, and stupor during clinical trials of efavirenz in combination with other antiretroviral agents. These symptoms were mild in 33.3%, moderate in 17.4%, and severe in 2% of patients; generally began the first or second day of therapy and often resolved after 2 to 4 weeks. Therapy was discontinued in 2.1% of patients due to these side effects.
Abnormal coordination, ataxia, cerebellar coordination and balance disturbances, convulsions, tremor, tinnitus, and vertigo have also been reported during postmarketing experience with efavirenz.[Ref]
Dermatologic
- Common (1% to 10%): Rash event (including rash, exfoliative rash, generalized rash, macular rash, maculopapular rash, pruritic rash, vesicular rash)
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, allergic reaction)
Efavirenz:
- Very common (10% or more): Skin rash of any grade (up to 26.3%), grade 2 rash (diffuse maculopapular rash, dry desquamation; 14.7%), grade 1 rash (erythema, pruritus; 10.7%)
- Common (1% to 10%): Pruritus
- Uncommon (0.1% to 1%): Grade 3 rash (vesiculation, moist desquamation, ulceration), grade 4 rash (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, necrosis requiring surgery, exfoliative dermatitis)
- Rare (less than 0.1%): Photoallergic dermatitis
- Frequency not reported: Nail disorders, skin discoloration, leukocytoclastic vasculitis
Emtricitabine:
- Common (1% to 10%): Vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discoloration (palmar-plantar hyperpigmentation)
- Postmarketing reports: Angioedema
Tenofovir DF:
- Very common (10% or more): Rash
- Rare (less than 0.1%): Angioedema[Ref]
Rashes associated with efavirenz were usually mild-to-moderate maculopapular skin eruptions. The median time to onset of rash was 11 days. In most patients who continued therapy, the rash resolved within 1 month. Treatment was discontinued in 1.7% of patients due to rash.
There was limited experience using efavirenz in patients who previously discontinued other nonnucleoside reverse transcriptase inhibitors due to rash. In 19 such patients formerly on nevirapine, about half developed a mild to moderate rash; 2 of those patients discontinued efavirenz because of the rash.
Erythema multiforme, pruritus, photoallergic dermatitis, and Stevens-Johnson syndrome have also been reported during postmarketing experience with efavirenz. Rash has also been reported during postmarketing experience with tenofovir.[Ref]
Other
- Common (1% to 10%): Fatigue
- Frequency not reported: Increased body weight
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Fever, pain, back pain
Efavirenz:
- Common (1% to 10%): Pain, fatigue
- Uncommon (0.1% to 1%): Flushing
- Frequency not reported: False-positive urine cannabinoid test results
- Postmarketing reports: Contraceptive failure (with an implantable hormonal contraceptive), asthenia
Emtricitabine:
- Common (1% to 10%): Pain, asthenia
Tenofovir DF:
- Very common (10% or more): Asthenia
- Frequency not reported: Higher 1,25 vitamin D levels
Antiretroviral therapy:
- Frequency not reported: Increased weight, increased blood lipid levels[Ref]
False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV-infected patients receiving efavirenz.
Flushing and asthenia have also been reported during postmarketing experience with efavirenz and tenofovir, respectively.[Ref]
Respiratory
- Common (1% to 10%): Sinusitis, upper respiratory tract infections, nasopharyngitis
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Increased cough, pneumonia, rhinitis
Efavirenz:
- Postmarketing reports: Dyspnea
Tenofovir DF:
- Postmarketing reports: Dyspnea[Ref]
Hepatic
- Common (1% to 10%): Elevated AST, elevated ALT
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Elevated bilirubin
- Frequency not reported: Severe acute exacerbations of hepatitis B
Efavirenz:
- Common (1% to 10%): Elevated ALT, elevated AST, elevated GGT
- Uncommon (0.1% to 1%): Acute hepatitis
- Postmarketing reports: Hepatic enzyme increase, hepatic failure, hepatitis
Emtricitabine:
- Common (1% to 10%): Elevated serum AST and/or elevated serum ALT, hyperbilirubinemia
- Frequency not reported: Liver failure, liver decompensation
Tenofovir DF:
- Common (1% to 10%): Increased transaminases
- Rare (less than 0.1%): Hepatic steatosis, hepatitis
- Frequency not reported: Lactic acidosis/severe hepatomegaly with steatosis
- Postmarketing reports: Elevated liver enzymes (primarily AST, ALT, GGT)[Ref]
Elevated AST (greater than 180 units/L in males and 170 units/L in females) and ALT (greater than 215 units/L in males and 170 units/L in females) have been reported in 3% and 2% of patients, respectively.
AST and ALT elevations were reported more often in patients who were coinfected with hepatitis B or C than in patients without coinfection.
Elevated bilirubin (greater than 2.5 times the upper limit of normal [2.5 x ULN]) has been reported with emtricitabine or tenofovir in up to 3% of patients.
Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and hepatitis B after discontinuation of emtricitabine or tenofovir and were associated with liver failure and liver decompensation in some of the emtricitabine-treated patients.
Some of the postmarketing reports of hepatic failure with efavirenz occurred in patients with no preexisting liver disease or other identifiable risk factors.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogs.
Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir.[Ref]
Hematologic
- Common (1% to 10%): Decreased neutrophils
- Frequency not reported: Increased hemoglobin
Emtricitabine:
- Common (1% to 10%): Neutropenia
- Uncommon (0.1% to 1%): Anemia[Ref]
Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients.[Ref]
Musculoskeletal
- Common (1% to 10%): Elevated creatine kinase
- Uncommon (0.1% to 1%): Myalgia
Emtricitabine or tenofovir DF:
- Common (1% to 10%): Arthralgia, myalgia
Emtricitabine:
- Very common (10% or more): Elevated creatine kinase
Efavirenz:
- Postmarketing reports: Arthralgia, myalgia, myopathy
Tenofovir DF:
- Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness
- Rare (less than 0.1%): Myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures)
- Frequency not reported: Decreased bone mineral density, increased biochemical markers of bone metabolism
Combination antiretroviral therapy:
- Frequency not reported: Osteonecrosis[Ref]
Elevated creatine kinase (greater than 990 units/L in males and 845 units/L in females) has been reported in up to 9% of patients.
Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.
Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy have also been reported during postmarketing experience with tenofovir.[Ref]
Genitourinary
- Common (1% to 10%): Hematuria
- Uncommon (0.1% to 1%): Glycosuria
Tenofovir DF:
- Uncommon (0.1% to 1%): Proteinuria
- Postmarketing reports: Polyuria[Ref]
Hematuria (greater than 75 red blood cells/high power field) and glycosuria (3+ or greater) have been reported in up to 3% and less than 1% of patients, respectively.
Proteinuria has also been reported during postmarketing experience with tenofovir.[Ref]
Renal
Tenofovir DF:
- Uncommon (0.1% to 1%): Increased creatinine, proximal renal tubulopathy (including Fanconi syndrome)
- Rare (less than 0.1%): Renal failure (acute and chronic), acute tubular necrosis, nephrogenic diabetes insipidus
- Frequency not reported: New onset or worsening renal impairment
- Postmarketing reports: Renal insufficiency, nephritis (including acute interstitial nephritis)[Ref]
Rhabdomyolysis, osteomalacia, hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, acute tubular necrosis, and nephrogenic diabetes insipidus have also been reported during postmarketing experience with tenofovir.[Ref]
Immunologic
- Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)
Efavirenz-, Emtricitabine-, and/or Tenofovir DF-Containing Products:
- Postmarketing reports: Autoimmune hepatitis, immune reconstitution syndrome[Ref]
Hypersensitivity
Efavirenz:
- Uncommon (0.1% to 1%): Hypersensitivity
- Postmarketing reports: Allergic reactions
Emtricitabine:
- Common (1% to 10%): Allergic reaction
Tenofovir DF:
- Postmarketing reports: Allergic reaction (including angioedema)[Ref]
Cardiovascular
Efavirenz:
- Frequency not reported: QT interval prolongation, torsades de pointes
- Postmarketing reports: Palpitations[Ref]
Endocrine
Efavirenz:
- Uncommon (0.1% to 1%): Gynecomastia
Tenofovir DF:
- Frequency not reported: Higher serum parathyroid hormone levels[Ref]
Gynecomastia has also been reported during postmarketing experience with efavirenz.[Ref]
Ocular
Efavirenz:
- Uncommon (0.1% to 1%): Blurred vision
- Postmarketing reports: Abnormal vision[Ref]
Blurred vision has also been reported during postmarketing experience with efavirenz.[Ref]
See also:
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Dovato
Dovato is a complete HIV-1 treatment regimen in one tablet that may be used in adults and children ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Zidovudine
Zidovudine systemic is used for HIV Infection, nonoccupational exposure, occupational exposure ...
Emtricitabine/tenofovir disoproxil
Emtricitabine/tenofovir disoproxil (brand name Truvada) is a combination antiviral tablet that may ...
Emtricitabine
Emtricitabine systemic is used for HIV Infection, nonoccupational exposure, occupational exposure
Tenofovir disoproxil
Tenofovir disoproxil systemic is used for hepatitis b, HIV Infection, nonoccupational exposure ...
References
1. (2001) "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals
2. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
3. (2003) "Product Information. Emtriva (emtricitabine)." Gilead Sciences
4. (2006) "Product Information. Atripla (efavirenz/emtricitabine/tenofovir)." Bristol-Myers Squibb
5. Frampton JE, Croom KF (2006) "Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate: triple combination tablet." Drugs, 66, p. 1501-12
6. (2006) "A once-daily combination tablet (Atripla) for HIV." Med Lett Drugs Ther, 48, p. 78-9
7. Cerner Multum, Inc. "Australian Product Information."
8. Cerner Multum, Inc. "UK Summary of Product Characteristics."
9. Arribas JR (2006) "Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate triple combination tablet: a viewpoint by jose R. Arribas." Drugs, 66, p. 1513-4
10. Carlan SJ, Bouldin S, Blust D, OBrien WF (2001) "Safety and efficacy of misoprostol orally and vaginally: A randomized trial." Obstet Gynecol, 98, p. 107-12
11. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, HillaireBuys D (2001) "Management of sudden psychiatric disorders related to efavirenz." Aids, 15, p. 1323-4
12. de La Garza CL, Paoletti-Duarte S, Garcia-Martin C, Gutierrez-Casares JR (2001) "Efavirenz-induced psychosis." AIDS, 15, p. 1911-2
13. Welch KJ, Morse A (2002) "Association between Efavirenz and Selected Psychiatric and Neurological Conditions." J Infect Dis, 185, p. 268-9
14. Puzantian T (2002) "Central nervous system adverse effects with efavirenz: case report and review." Pharmacotherapy, 22, p. 930-3
15. Treudler R, Husak R, Raisova M, Orfanos CE, Tebbe B (2001) "Efavirenz-induced photoallergic dermatitis in HIV." AIDS, 15, p. 1085-6
16. Domingo P, Barcelo M (2002) "Efavirenz-induced leukocytoclastic vasculitis." Arch Intern Med, 162, p. 355-6
17. Colebunders R, Vanwolleghem T, Meurrens P, Moerman F (2004) "Efavirenz-associated Stevens-Johnson syndrome." Infection, 32, p. 306-7
18. Callens S, De Schacht C, Huyst V, Colebunders R (2003) "Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment." J Infect, 47, p. 188-9
19. Perazella MA (2003) "Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity." Am J Med Sci, 325, p. 349-62
20. Castillo R, Pedalino RP, El-Sherif N, Turitto G (2002) "Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia." Ann Pharmacother, 36, p. 1006-8
21. Mercie P, Viallard JF, Thiebaut R, Faure I, Rispal P, Leng B, Pellegrin JL (2001) "Efavirenz-associated breast hypertrophy in HIV-infected patients." Aids, 15, p. 126-9
22. Caso JAA, Prieto JD, Casas E, Sanz J (2001) "Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz." Aids, 15, p. 1447-8
23. Caso JA, Prieto Jde M, Casas E, Sanz J (2001) "Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz." AIDS, 15, p. 1447-8
24. Qazi NA, Morlese JF, King DM, Ahmad RS, Gazzard BG, Nelson MR (2002) "Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis." AIDS, 16, p. 506-7
Frequently asked questions
More about Atripla (efavirenz / emtricitabine / tenofovir disoproxil)
- Check interactions
- Compare alternatives
- Reviews (105)
- Drug images
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: antiviral combinations
Patient resources
Professional resources
Related treatment guides
Further information
Atripla side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.